

# Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers

L Kadouri<sup>\*1</sup>, Z Kote-Jarai<sup>2</sup>, A Hubert<sup>1</sup>, M Baras<sup>3</sup>, D Abeliovich<sup>4</sup>, T Hamburger<sup>1</sup>, T Peretz<sup>1</sup> and RA Eeles<sup>2,5</sup>

<sup>1</sup>Sharett Institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel; <sup>2</sup>Cancer Research UK Section of Cancer Genetics, The Institute of Cancer Research, Sutton, UK; <sup>3</sup>Braun School of Public Health, Hebrew University-Hadassah Medical Center, Jerusalem, Israel; <sup>4</sup>Human Genetic Laboratories, Hebrew University-Hadassah Medical Center, Jerusalem, Israel; <sup>5</sup>The Royal Marsden NHS Foundation Trust, Sutton, UK

Variation in penetrance estimates for BRCA1/2 carriers suggests that other environmental and genetic factors may modify cancer risk in carriers. The GSTM1, T1 and P1 isoenzymes are involved in metabolism of environmental carcinogens. The *GSTM1* and *GSTT1* gene is absent in a substantial proportion of the population. In *GSTP1*, a single-nucleotide polymorphism that translates to Ile112Val was associated with lower activity. We studied the effect of these polymorphisms on breast cancer (BC) risk in BRCA1/2 carriers. A population of 320 BRCA1/2 carriers were genotyped; of them 262 were carriers of one of the three Ashkenazi founder mutations. Two hundred and eleven were affected with BC (20 also with ovarian cancer (OC)) and 109 were unaffected with BC (39 of them had OC). Risk analyses were conducted using Cox proportional hazard models adjusted for origin (Ashkenazi vs non-Ashkenazi). We found an estimated BC HR of 0.89 (95% CI 0.65–1.12,  $P=0.25$ ) and 1.11 (95% CI 0.81–1.52,  $P=0.53$ ) for the null alleles of *GSTM1* and *GSTT1*, respectively. For *GSTP1*, HR for BC was 1.36 (95% CI 1.02–1.81,  $P=0.04$ ) for individuals with Ile/Val, and 2.00 (95% CI 1.18–3.38) for carriers of the Val/Val genotype ( $P=0.01$ ). An HR of 3.20 (95% CI 1.26–8.09,  $P=0.01$ ), and younger age at BC onset ( $P=0.2$ ), were found among Val/Val, BRCA2 carriers, but not among BRCA1 carriers. In conclusion, our results indicate significantly elevated risk for BC in carriers of BRCA2 mutations with *GSTP1*-Val allele with dosage effect, as implicated by higher risk in homozygous Val carriers. The *GSTM1*- and *GSTT1*-null allele did not seem to have a major effect.

British Journal of Cancer (2008) 98, 2006–2010. doi:10.1038/sj.bjc.6604394 www.bjcancer.com

Published online 27 May 2008

© 2008 Cancer Research UK

**Keywords:** breast cancer; BRCA1/2; glutathione-S-transferase; GSTP1 polymorphism; modifiers

The variability of cancer risk among BRCA1/2 carriers (Struewing *et al*, 1997; Ford *et al*, 1998; Thorlacius *et al*, 1998; Antoniou *et al*, 2003) suggests a role for environmental and genetic modifiers. The impaired DNA-repair mechanism in carriers of BRCA1/2 mutation (Boulton, 2006) may result in higher vulnerability to reduced activity of other genes that participate in maintaining genome stability. The glutathione-S-transferase superfamily of enzymes participates in protection against exogenous and endogenous oxidative damage (Hayes and Pulford, 1995). They conjugate xenobiotics, such as herbicides, insecticides and other environmental carcinogens, and anticancer agents (alkylating agents, platinum compounds) to glutathione to facilitate excretion. In addition, endogenous electrophile molecules produced through metabolism of lipid and DNA products of oxidative stress, as well as oxidative metabolites of oestrogen, the catechol oestrogen, are detoxified by these enzymes (Cavalieri *et al*, 2000; Dawling *et al*, 2004).

Homozygous absence of both alleles coding for the *GSTM1* (Seidegard *et al*, 1985) and *GSTT1* (Pemble *et al*, 1994) are commonly found in various populations (50 and 20% respectively; Rebbeck, 1997). Elevated DNA adducts, sister-chromatid exchange and somatic genetic mutation have been demonstrated in carriers of null *GSTM1* and *GSTT1* genotypes (Rebbeck, 1997). In *GSTP1* gene, a polymorphism of A315G encodes substitution of the wild-

type isoleucine to valine at position 105 (Ile105Val). The valine variant was reported to have a reduced activity when recombinantly expressed in *Escherichia coli* (Zimniak *et al*, 1994).

The role of these genes in breast cancer (BC) has been evaluated through numerous case-control studies yielding conflicting results. In a meta-analysis in 1999 (Dunning *et al*, 1999), the *GSTP1* Ile/Val genotype had odds ratio (OR) for BC of 1.6 ( $P=0.02$ ). *GSTM1* was significantly associated with postmenopausal BC and for *GSTT1*, a moderate effect of 1.5 risk elevation could not be excluded. A recent large case-control study in Shanghai observed an elevated BC risk of approximately 2 among the *GSTP1*-val homozygotes, which was similar among pre- and postmenopausal women (Egan *et al*, 2004). The authors also reported an updated meta-analysis based mainly on studies in the Caucasian population, which supports null results for these three polymorphisms. A subsequent pooled analysis based on approximately 2000 cases and controls was also negative for the three GST polymorphisms (Vogl *et al*, 2004).

In this study, we report the effect of these polymorphisms on BC risk and age at onset among BRCA1/2 carriers (Figures 1 and 2).


## METHODS

### Subjects and methods


**Study population** The study population has been reported previously (Kadouri *et al*, 2004a). In summary, blood samples

\*Correspondence: Dr L Kadouri; E-mail: luna@hadassah.org.il

Received 2 January 2008; revised 26 March 2008; accepted 10 April 2008; published online 27 May 2008



**Figure 1** Probabilities of BC with age according to *GSTP1* genotypes (Ile/Ile, Ile/Val, Val/Val) among *BRCA1* carriers (analyses were adjusted to origin, Ashkenazi vs non-Ashkenazi).



**Figure 2** Probabilities of BC with age according to *GSTP1* genotypes (Ile/Ile, Ile/Val, Val/Val) among *BRCA2* carriers (analyses were adjusted to origin, Ashkenazi vs non-Ashkenazi).

from 320 *BRCA1/2* carriers were collected through two centres: 240 carriers were identified by the oncology department and the cancer genetic clinic in the Hadassah Medical Centre in Jerusalem, Israel, and 80 at the cancer genetic carrier clinic in the Royal Marsden NHS Foundation Trust, London, UK. Cases were tested on the basis of a family history of BC and/or ovarian cancer (OC), or on the basis of their Ashkenazi origin. All the cases from Jerusalem were of Ashkenazi origin; of them all, but one, carried one of the three Ashkenazi founder mutations (132 cases: 185delAG, 32 cases: 5382insC in *BRCA1* and 75 cases: 6174delT in *BRCA2*, one carried other *BRCA2* mutations). The carriers from UK included 23 carriers of the Ashkenazi founder mutations (12 cases: 185delAG, 5 cases: 5382insC and 5 cases: 6174delT) and two carriers of both 185delAG and 6174delT) and 56 carriers of other mutations (47 *BRCA1*; 9 *BRCA2*, specific mutation have been reported elsewhere; Kadouri et al, 2004b). Of the 320 carriers, 191 were affected with BC, 39 with OC and 20 with both cancers. Seventy of the mutation carriers were unaffected.

### Genotyping

DNA was salt-extracted from blood samples by standard methods. *GSTM1* and *GSTT1* genotypes were determined by PCR

amplification and agarose-gel electrophoresis. The *INFA5* (5'-ggcacaacaggtagtagggc-3', 5'-gccacaggagctctgacac-3') gene was used as an internal control; this method conclusively identifies the null genotypes (homozygous deletion of the gene). Homozygous non-deleted and heterozygous genotypes were not distinguished from each other. The *GSTP1* (Ile105Val) genotypes were determined by PCR-RFLP. For all PCR reactions, 25 ng of genomic DNA was used in a 15- $\mu$ l reaction mixture containing 1.5 mM MgCl<sub>2</sub>, 6 pM of each primer, 0.5 U of Amplitaq Gold polymerase (The Perkin Elmer Corp. Norwalk, CT, USA) and were run in a Hybaid Touchdown PCR machine. Primers were as follows: *GSTM1*, 5'-ctgccctacttgattgatggg-3', 5'-ctggattgtagcagatcatgc-3'; *GSTT1*, 5'-ttccttactgttcctcacatctc-3', 5'-tcaccggatcatggcagca-3'; *GSTP1*: 5'-accagggtctctatgggaa-3', 5'-tgagggcacaagaagccct-3'. Annealing temperature was 55°C for *GSTM1* and *GSTP1*, and 66°C for *GSTT1*. Assignment of the *GSTP1* Ile (ACA TCT) and Val (ACG TCT) genotype was made by digestion of the PCR products on the basis of the RFLP with *Bsm*AI (New England Biolabs, Hertfordshire, UK). All PCR products were separated on 3% agarose gels with 2  $\mu$ l/100 ml of ethidium bromide. Affected and unaffected samples were randomly located in the plates, a control sample was localised in each plate and five of the samples were genotyped twice with 100% concordance for the three genes. Call rates were high with one sample that could not be genotyped at all and an additional failure in *GSTT1* and *GSTP1* genotypes.

### Statistical analysis

The effects of *GST* genotypes on BC risk in mutation carriers were evaluated using a COX proportional hazards model. Participants were followed up retrospectively from date of birth to several possible outcomes. The outcome in women affected with BC was recorded as the age at first BC diagnosis. Women unaffected with BC were censored at the date of OC diagnosis, prophylactic surgery, date of last follow up or death. Since distributions of age and disease status were different in the Ashkenazi and non-Ashkenazi populations, the analyses were adjusted for ethnic origin. Although selection of participants is partly based on outcome, this method of analysis was used previously for risk estimation in carriers (Rebbeck et al, 1999; Levy-Lahad et al, 2001; Kadouri et al, 2004a). In our study (Kadouri et al, 2001) on the modifying effect of the androgen receptor-CAG-repeat length in *BRCA* carriers, we compared COX proportional hazard models to a variant of the log rank designed to overcome selection bias by comparison of outcome to expected penetrance according to the literature. Since estimated risks were almost similar in both methods, in the current paper we have used COX proportional hazards models. The *GSTM1* and *GSTT1* genotypes were classified as either null (i.e., homozygous deletion) or non-deleted (i.e., heterozygous or homozygous for the presence of the gene). For *GSTP1* polymorphism, where there were more than two genotypes, ORs were compared with the more common genotype, the Ile homozygous genotype. Comparison of ages at BC onset were calculated by ANOVA. We adjusted the *P*-values for multiple comparisons following HOLM's procedure both for pairwise comparisons of origin (Ashkenazi/non-Ashkenazi) with the *GST* genotypes and for the COX regression models as shown in Table 1.

### RESULTS

The frequency of the *GSTM1*- and *GSTT1*-null and *GSTP1* alleles in our Ashkenazi and non-Ashkenazi populations were as follows: *GSTM1* null in 52.1 vs 55.2% ( $P=0.77$ ) and *GSTT1* null in 10.5 vs 26.6% ( $P=0.03$ ), respectively. *GSTP1* Ile/Ile, Ile/Val and Val/Val were found in 64.6, 30.4 and 4.9% of the Ashkenazi population, compared with 49.1, 40.4 and 10.5% in non-Ashkenazi,

**Table 1** *GSTM1*, *T1* and *P1* allele frequencies and BC HR in *BRCA1/2* carriers (adjusted for origin, Ashkenazi vs non-Ashkenazi)

Genotype	BC- (n = 109) no. (%)	BC+ (n = 211) no. (%)	Average age at BC onset (years)	Breast cancer HR (95% CI)	P-value
<b><i>GSTM1</i> (n = 320)</b>					
Present	46 (42.2)	106 (50.2)	41.4	1	0.25 <sup>a</sup>
Null	63 (57.8)	105 (49.8)	42.9	0.89 (0.65–1.12)	
<b><i>GSTT1</i> (n = 319)</b>					
Present	84 (77.8)	158 (74.9)	42.5	1	0.53 <sup>b</sup>
Null	24 (22.2)	53 (25.1)	41.3	1.11 (0.81–1.52)	
<b><i>GSTP1</i> (n = 319)</b>					
Ile/Ile	76 (70.6)	121 (57.3)	42.1	1	0.04 <sup>c</sup>
Ile/Val	29 (26.6)	74 (35.1)	42.6	1.36 (1.02–1.81)	
Val/Val	3 (2.8)	16 (7.6)	40.5	2.00 (1.18–3.38)	

BC-, no BC; BC+, with BC; CI, confidence interval; HI, hazard ratio. Corresponding P-values after correction for multiple comparisons are as follows: <sup>a</sup>0.50, <sup>b</sup>0.53, <sup>c</sup>0.12 and <sup>d</sup>0.03.

**Table 2** *GSTP1* allele frequencies and BC HR in *BRCA1* and *BRCA2* carriers (adjusted for origin, Ashkenazi vs non-Ashkenazi)<sup>a</sup>

<i>GSTP1</i>	<i>BRCA1</i> (n = 228)			<i>BRCA2</i> (n = 90)		
	BC- (n = 78) no. (%)	BC+ (n = 150) no. (%)	Breast cancer HR (95% CI, P)	BC- (n = 29) no. (%)	BC+ (n = 61) no. (%)	Breast cancer HR (95% CI, P)
Ile/Ile	53 (67.9)	86 (57.3)	1	22 (75.9)	35 (57.4)	1
Age at BC		40.5 years			46.6 years	
Ile/Val	22 (28.2)	54 (36)	1.22 (0.87–1.72, P = 0.24)	7 (24.1)	20 (32.8)	1.50 (0.86–2.59, P = 0.15)
Age at BC		42.6 years			42.6 years	
Val/Val	3 (3.9)	10 (6.7)	1.38 (0.71–2.70, P = 0.15)	0	6 (9.8)	3.20 (1.26–8.09, P = 0.01)
Age at BC		40.1 years			41.2 years	

BC-, no BC; BC+, with BC; CI, confidence interval; HI, hazard ratio. <sup>a</sup>Compound heterozygotes were excluded from these analyses.

respectively ( $P = 0.03$ ), and all were in Hardy-Weinberg in both populations.

Table 1 shows the frequencies of the *GSTM1*, *GSTT1* and *GSTP1* genotypes in *BRCA1/2* carriers both with and without BC, and the corresponding hazard ratios (HR). The *GSTM1*- and *GSTT1*-null genotypes were not associated with BC risk. Frequency of the *GSTM1*-null allele was non-significantly lower in BC cases (49.8%) than in BC-free *BRCA1/2* mutation carriers (57.8%), and the estimated HR was 0.89 (95% CI 0.65–1.12,  $P = 0.25$ ). The corresponding frequencies for the *GSTT1*-null allele were 25.1 and 22.2% in BC cases and in BC-free carriers with a non-significant HR of 1.11 (95% CI 0.81–1.52,  $P = 0.53$ ). There was, however, evidence of increasing BC risk with increasing number of *GSTP1*-Val alleles; the HR for developing BC was 1.36 (95% CI 1.02–1.81,  $P = 0.04$ ) and 2.00 (95% CI 1.18–3.38,  $P = 0.01$ ), respectively, for *Ile/Val* heterozygotes and *Val/Val* homozygotes, as compared with that for *Ile/Ile* homozygotes (see P-values after correction for multiple comparisons in the footnote of Table 1).

In a separate analysis for the role of *GSTP1* genotypes in *BRCA1* and *BRCA2* carriers (Table 2, Figure 2), a significant effect was found among the *BRCA2* carriers. The HR for developing BC was 1.50 (95% CI 0.86–2.59,  $P = 0.6$ ) and 3.20 (95% CI 1.26–8.09,  $P = 0.01$ ), respectively, for *Ile/Val* heterozygotes and *Val/Val* homozygotes, as compared with that for *Ile/Ile* homozygotes. Younger mean age of 41.2 years at BC onset was found among *Val/Val* homozygotes as compared with 46.6 years in *Ile/Ile* homozygotes ( $P = 0.2$ ). In *BRCA1* carriers, the effect of the *GSTP1*-Val allele was non-significant (Table 2, Figure 1).

## DISCUSSION

Our results do not show a major effect of the null genotypes of the *GSTM1* and *GSTT1* on BC risk in *BRCA1/2* mutation carriers.

However, the *GSTP1*-Val/Val allele was associated with approximately twofold BC risk in *BRCA1/2* carriers. In *BRCA2* carriers, a significant HR of 3.2 was found in homozygotes for the Val allele, whereas the effect among *BRCA1* carriers was non-significant. To our knowledge this is the first report of an effect of *GST* polymorphism in *BRCA1/2* carriers. A major limitation of our study is the survival bias due to inclusion of individuals while alive. This is an important consideration also regarding previous genetic risk modifiers reported among *BRCA1/2* carriers, since the effect of these modifiers on survival is unknown. The effect of the *GST*-Val allele on BC prognosis contradicted in previous studies (Goode et al, 2002; Yang et al, 2005). Therefore, larger studies based on incident cases are warranted.

The *GSTP1* isoenzyme is highly expressed in the mammary epithelium, both in normal and in tumor cells (Forrester et al, 1990; Kelley et al, 1994). It has been shown that methylation of the promoter (Arai et al, 2006) and low expression of the *GSTP1* gene is associated with poor prognosis in BC patients treated with chemotherapy (Arai et al, 2006). In addition to its role in detoxifying electrophilic molecules from exogenous exposures, the *GSTP1* gene has an important role in the metabolism of estradiol derivatives (Cavalieri et al, 2000; Dawling et al, 2004). It reduces the concentration of oestrogen quinones, thereby reducing the potential of these oxidative oestrogen metabolites to induce DNA damage. It is possible that in cells, which are deficient in functional *BRCA1* or *BRCA2*, key proteins in DNA-damage repair, the DNA will be vulnerable to oxidative damage. The role of the *BRCA2* protein in DNA double-strand break (DSB) repair is well established (Boulton, 2006). The *BRCA2* protein has a distal role in the DNA-repair machinery (Boulton, 2006). It forms a complex with the *RAD51* protein, which is essential for DNA repair through homologous recombination (Davies et al, 2001). However, the direct function of *BRCA1* in DSB repair is less clear, although a more proximal role in sensing and regulation of cellular response

to DNA damage has been suggested by several recent papers (Boulton, 2006). More importantly, BRCA1 upregulates the expression of genes involved in antioxidant response, including GST genes (Bae et al, 2004). In accordance, BRCA1 deficiency conferred sensitivity to several oxidising agents in cell lines (Bae et al, 2004). The lack of effect in BRCA1 carriers could be related to the already high oxidative stress in cells deficient in the BRCA1 protein; the addition of low active GSTP1 does not significantly add to the process of tumorigenesis. However in BRCA2 carriers, low level of active GSTP1 results in higher DNA damage properly sensed by BRCA1, but ineffectively corrected by the BRCA2 complex.

Several modifier genes were reported in carriers of BRCA1/2 mutation. A modifying effect has been confirmed by two or more separate studies for two of these modifiers. Interestingly, in both genes, the effect differed among BRCA1 and BRCA2 carriers. A rare polymorphism in the RAD51 gene was associated with BC risk in BRCA2 carriers (Levy-Lahad et al, 2001; Wang et al, 2001; Kadouri et al, 2004a). Recently, a large study among approximately 8500 mutation carriers confirmed a modifying effect for the homozygous, but not the heterozygous, RAD51 135 g/c polymorphism (Antoniou et al, 2007). On the other hand, a polymorphic CAG-repeat length in the AIB1, a coactivator of the oestrogen receptor, was found to modify BC risk in BRCA1 carriers (Rebbeck et al, 2001; Kadouri et al, 2004b). Two recent, large studies did not observe a modifying effect for the AIB1-CAG repeat among BRCA1/2 carriers (Hughes et al, 2005; Spurdle et al, 2006). It is possible that these larger studies included heterogeneous popula-

tion both genetically and clinically; therefore, association may be either lost or exaggerated. Indeed, distributions of three polymorphisms previously reported by us, the AR-CAG repeat (Kadouri et al, 2001), RAD51-g/c-SNP (Kadouri et al, 2004a) and the AIB1-polyglutamine chain length (Kadouri et al, 2004b), as well as the GSTP1 in the current study, were significantly different among Ashkenazi Jews as compared with British Caucasian women. Since we included two distinct populations, we were able to effectively adjust for origin.

In conclusion, in the present study we report a modifying effect of the GSTP1 gene in BRCA2 but not BRCA1 carriers. Carriers of homozygous Val/Val allele, a less active variant of the GSTP1 protein, had an approximately threefold risk for BC and younger age at onset as compared with Ile/Ile carriers. This adds to the mounting evidence suggesting differences in molecular mechanisms involved in normal function and tumor formation in BRCA1 and BRCA2 carriers. These positive results obtained from a small population of BRCA2 carriers should prompt a larger study in other populations as well.

## ACKNOWLEDGEMENTS

LK was supported by Barclay fellowship through the British Council, for which we are most grateful. We thank the Radlett Synagogue Community for its tremendous support for this study. ZKJ was supported by a legacy from the late Marion Silcock. This work was supported by the Institute of Cancer Research, UK.

## REFERENCES

- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lallo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 72: 1117–1130
- Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bibnon Y, (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OL, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Gorski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, (EMBRACE), Schmutzler RK, Vermold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N, (kConFab), Kirchhoff T, Offit K, Freidman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Leibkowitz F, Raskin L, Andrulis IL, Ilyushik E, Ozelik H, Devilee P, Vreeswijk MPG, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpovaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G, (CIMBA) (2007) RAD51 135G-C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet* 81: 1186–1200
- Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2006) Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. *Breast Cancer Res Treat* 200: 169–176
- Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, Rosen EM (2004) BRCA1 induces antioxidant gene expression and resistance to oxidative stress. *Cancer Res* 64: 7893–7909
- Boulton SJ (2006) Cellular functions of the BRCA tumor suppressor proteins. *Biochem Soc Trans* 34: 633–645
- Cavaliere E, Frenkel K, Liehr JG, Rogan E, Roy D (2000) Estrogens as endogenous genotoxic agents: DNA adducts and mutations. *J Natl Cancer Inst Monogr* 27: 75–93
- Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. *Mol Cell* 7: 273–282
- Dawling S, Hachey DL, Roodi N, Parl FF (2004) *In vitro* model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogen 2- and 4-hydroxyestradiol. *Chem Res Toxicol* 17: 1258–1264
- Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 8: 843–854
- Egan KM, Cai Q, Shu XO, Jin F, Zhu TL, Dai O, Gao YT, Zheng W (2004) Genetic polymorphisms in GSTM1, GSTP1 and GSTT1 and the risk of breast cancer: Shanghai Breast Cancer Study and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 13: 197–204
- Ford D, Easton DF, Stratton MR, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, the Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. *Am J Hum Genet* 62: 676–689
- Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ, Powis G, Wolf CR (1990) Expression of glutathione S-transferase and cytochrome P450 in normal and tumor breast tissue. *Carcinogenesis* 11: 2163–2170
- Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah DP (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. *Cancer Res* 62: 3052–3057
- Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol* 30: 445–600
- Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau U, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Sobol H, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM (2005) Breast cancer risk in BRCA1

- and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. *Int J Cancer* 117(2): 230–233
- Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles R (2001) CAG and GGC repeat polymorphism in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. *Br J Cancer* 85: 36–40
- Kadouri L, Kote-Jarai Z, Easton EF, Hubert A, Hamoudi R, Glaser B, Abeliovich D, Peretz T, Eeles RA (2004b) Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. *Int J Cancer* 108: 399–403
- Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T (2004a) A single nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 but not in BRCA1 carriers or non-carriers. *Br J Cancer* 90: 2002–2005
- Kelley MK, Engqvist-Goldstein A, Montali JA, Whealey JB, Schmidt Jr DE, Kauvar LM (1994) Variability of glutathione S-transferase isoenzyme patterns in matched normal and cancer human breast tissue. *Biochem J* 3: 843–848
- Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R (2001) A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. *Proc Natl Acad Sci USA* 98: 3232–3236
- Pemble S, Schroeder KR, Spenser SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB (1994) Human glutathione S-transferase o (GSTT1): cDNA cloning and characterization of a genetic polymorphism. *Biochem J* 300: 271–276
- Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. *Cancer Epidemiol Biomarkers Prev* 6: 733–743
- Rebbeck TR, Kantoff PW, Kirthivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. *Am J Hum Genet* 64: 1371–1377
- Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Gaerber JE, Lynch HT, Weber BL, Brown M (2001) Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. *Cancer Res* 61(14): 5420–5424
- Seidegard J, DePierre JW, Pero RW (1985) Hereditary interindividual differences in the glutathione transferase activity towards trans-stilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s). *Carcinogenesis* 6: 1211–1216
- Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenxix-Trench G, Australian Breast Cancer Family Study, Australian Jewish Breast Cancer Study, Breast Cancer Family Registry, Interdisciplinary Health Research, International Team on Consortium for Research into Familial Breast Cancer and Epidemiological Study of Familial Breast Cancer (2006) The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 15(1): 76–79
- Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 336: 1401–1408
- Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutations. *Lancet* 352: 1337–1339
- Vogl FD, Taioli E, Maugard C, Zheng W, Ribeiro Pinto LF, Ambrosone C, Parl FF, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P, Boffetta P (2004) Glutathione S-transferase M1, T1, and P1 and breast cancer: a pooled analysis. *Cancer Epidemiol Biomarkers Prev* 13: 1473–1479
- Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP (2001) A single nucleotide polymorphism in the 5' untranslated region of RAD51 risk of cancer among BRCA1/2 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 10: 955–960
- Yang G, Shu X, Ruan Z, Cai Q, Jin F, Gao Y, Zheng W (2005) Genetic polymorphisms in glutathione S-transferases genes (GSTM1, GSTT1 GSTP1) and survival after chemotherapy for invasive breast carcinoma. *Cancer* 103: 52–58
- Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC (1994) Naturally occurring human glutathione S-transferase GSTP1 isoforms with isoleucine and valine in position 105 differ in enzymic properties. *Eur J Biochem* 224: 893–899